Biomedical Engineering Reference
In-Depth Information
4. Hughes TP, et al. Monitoring disease response to tyrosine kinase inhibitor therapy in CML.
Hematology Am Soc Hematol Educ Program. 2009:477-87
5. Table of pharmacogenomic biomarkers in drug labels. Last accessed 5 Jan 2012
6. Schilsky RL (2010) Personalized medicine in oncology: the future is now. Nat Rev Drug
Discov 9:363-366
7. McDermott U et al (2009) Personalized cancer therapy with selective kinase inhibitors: an
emerging paradigm in medical oncology. J Clin Oncol 27:5650-5659
8. Cortes JE et al (2009) Pharmacokinetic/pharmacodynamic correlation and blood-level testing
in imatinib therapy for chronic myeloid leukemia. Leukemia 23:1537-1544
9. von Mehren M et al (2011) Correlations between imatinib pharmacokinetics, pharmacody-
namics, adherence, and clinical response in advanced metastatic gastrointestinal stromal
tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37:291-299
10. Stearns V et al (2003) Active tamoxifen metabolite plasma concentrations after coadministra-
tion of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst
95:1758-1764
11. Borges S et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen
metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther
80:61-74
12. Widmer N et al (2004) Determination of imatinib (gleevec) in human plasma by solid-phase
extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B Analyt
Technol Biomed Life Sci 803:285-292
13. Krause DS et al (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med
353:172-187
14. Oliff A et al (1996) New molecular targets for cancer therapy. Sci Am 275:144-149
15. Larson RA et al (2008) Imatinib pharmacokinetics and its correlation with response and
safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood
111:4022-4028
16. Picard S et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and
molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:
3496-3499
17. Demetri GD et al (2009) Imatinib plasma levels are correlated with clinical benefit in patients
with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27(19):3141-3147
18. Peng B et al (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879-894
19. Widmer N et al (2008) Relationship of imatinib-free plasma levels and target genotype with
efficacy and tolerability. Br J Cancer 98:1633-1640
20. Widmer N et al (2010) Imatinib plasma levels: correlation with clinical benefit in GIST
patients. Br J Cancer 102:1198-1199
21. Badalamenti G et al (2007) Gastrointestinal stromal tumors (GISTs): focus on histopatho-
logical diagnosis and biomolecular features. Ann Oncol 18(Suppl 6):vi136-vi140
22. Geyer CE et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
N Engl J Med 355:2733-2743
23. Le TC et al (2008) New developments in multitargeted therapy for patients with solid tumours.
Cancer Treat Rev 34:37-48
24. Mitsudomi T et al (2005) Mutations of the epidermal growth factor receptor gene predict
prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with
postoperative recurrence. J Clin Oncol 23:2513-2520
25. Cadranel J et al (2011) Genetic profiling and epidermal growth factor receptor-directed ther-
apy in nonsmall cell lung cancer. Eur Respir J 37:183-193
26. Commander H et al (2011) Vandetanib: first global approval. Drugs 71:1355-1365
27. Flaherty KT et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N
Engl J Med 363:809-819
28. Sasaki T et al (2011) New strategies for treatment of ALK-rearranged non-small cell lung
cancers. Clin Cancer Res 17:7213-7218
